The Progress of Induced Pluripotent Stem Cells as Models of Parkinson’s Disease
In recent years, induced pluripotent stem cells (iPSCs) were widely used for investigating the mechanisms of Parkinson’s disease (PD). Somatic cells from patients with SNCA (α-synuclein), LRRK2 (leucine-rich repeat kinase 2), PINK1 (PTEN induced putative kinase 1), Parkin mutations, and at-risk indi...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Stem Cells International |
| Online Access: | http://dx.doi.org/10.1155/2016/4126214 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850161927774273536 |
|---|---|
| author | Ji-feng Kang Bei-sha Tang Ji-feng Guo |
| author_facet | Ji-feng Kang Bei-sha Tang Ji-feng Guo |
| author_sort | Ji-feng Kang |
| collection | DOAJ |
| description | In recent years, induced pluripotent stem cells (iPSCs) were widely used for investigating the mechanisms of Parkinson’s disease (PD). Somatic cells from patients with SNCA (α-synuclein), LRRK2 (leucine-rich repeat kinase 2), PINK1 (PTEN induced putative kinase 1), Parkin mutations, and at-risk individuals carrying GBA (β-glucocerebrosidase) mutations have been successfully induced to iPSCs and subsequently differentiated into dopaminergic (DA) neurons. Importantly, some PD-related cell phenotypes, including α-synuclein aggregation, mitophagy, damaged mitochondrial DNA, and mitochondrial dysfunction, have been described in these iPSCs models, which further investigated the pathogenesis of PD. In 2007, Takahashi et al. and Vodyanik et al. generated iPSCs from human somatic cells for the first time. Since then, patients derived iPSCs were applied for disease modeling, drug discovery and screening, autologous cell replacement therapy, and other biological applications. iPSC research has now become a hot topic in a wide range of fields. This review summarizes the recent progress of PD patients derived iPSC models in pathogenic mechanism investigation and potential clinical applications, especially their promising strategy in pharmacological study and DA neurons transplantation therapy. However, the challenges of iPSC transplantation still exist, and it has a long way to go before it can be used in clinical application. |
| format | Article |
| id | doaj-art-fd72e0b05f1f4bcaaf37f434173930a5 |
| institution | OA Journals |
| issn | 1687-966X 1687-9678 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Stem Cells International |
| spelling | doaj-art-fd72e0b05f1f4bcaaf37f434173930a52025-08-20T02:22:40ZengWileyStem Cells International1687-966X1687-96782016-01-01201610.1155/2016/41262144126214The Progress of Induced Pluripotent Stem Cells as Models of Parkinson’s DiseaseJi-feng Kang0Bei-sha Tang1Ji-feng Guo2Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, ChinaDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, ChinaDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, ChinaIn recent years, induced pluripotent stem cells (iPSCs) were widely used for investigating the mechanisms of Parkinson’s disease (PD). Somatic cells from patients with SNCA (α-synuclein), LRRK2 (leucine-rich repeat kinase 2), PINK1 (PTEN induced putative kinase 1), Parkin mutations, and at-risk individuals carrying GBA (β-glucocerebrosidase) mutations have been successfully induced to iPSCs and subsequently differentiated into dopaminergic (DA) neurons. Importantly, some PD-related cell phenotypes, including α-synuclein aggregation, mitophagy, damaged mitochondrial DNA, and mitochondrial dysfunction, have been described in these iPSCs models, which further investigated the pathogenesis of PD. In 2007, Takahashi et al. and Vodyanik et al. generated iPSCs from human somatic cells for the first time. Since then, patients derived iPSCs were applied for disease modeling, drug discovery and screening, autologous cell replacement therapy, and other biological applications. iPSC research has now become a hot topic in a wide range of fields. This review summarizes the recent progress of PD patients derived iPSC models in pathogenic mechanism investigation and potential clinical applications, especially their promising strategy in pharmacological study and DA neurons transplantation therapy. However, the challenges of iPSC transplantation still exist, and it has a long way to go before it can be used in clinical application.http://dx.doi.org/10.1155/2016/4126214 |
| spellingShingle | Ji-feng Kang Bei-sha Tang Ji-feng Guo The Progress of Induced Pluripotent Stem Cells as Models of Parkinson’s Disease Stem Cells International |
| title | The Progress of Induced Pluripotent Stem Cells as Models of Parkinson’s Disease |
| title_full | The Progress of Induced Pluripotent Stem Cells as Models of Parkinson’s Disease |
| title_fullStr | The Progress of Induced Pluripotent Stem Cells as Models of Parkinson’s Disease |
| title_full_unstemmed | The Progress of Induced Pluripotent Stem Cells as Models of Parkinson’s Disease |
| title_short | The Progress of Induced Pluripotent Stem Cells as Models of Parkinson’s Disease |
| title_sort | progress of induced pluripotent stem cells as models of parkinson s disease |
| url | http://dx.doi.org/10.1155/2016/4126214 |
| work_keys_str_mv | AT jifengkang theprogressofinducedpluripotentstemcellsasmodelsofparkinsonsdisease AT beishatang theprogressofinducedpluripotentstemcellsasmodelsofparkinsonsdisease AT jifengguo theprogressofinducedpluripotentstemcellsasmodelsofparkinsonsdisease AT jifengkang progressofinducedpluripotentstemcellsasmodelsofparkinsonsdisease AT beishatang progressofinducedpluripotentstemcellsasmodelsofparkinsonsdisease AT jifengguo progressofinducedpluripotentstemcellsasmodelsofparkinsonsdisease |